目的 探究盐酸安罗替尼对晚期非小细胞肺癌(Non-small-cell Lung Carcinoma,NSCLC)患者生存质量的影响.方法 方便选择2022年1-10月新沂市人民医院收治的122例NSCLC患者作为研究对象,采用随机双盲法将患者分成对照组(n=61)和观察组(n=61).对照组进行常规化疗,观察组采用常规化疗联合盐酸安罗替尼治疗.对比两组肿瘤标志物水平、生活质量和不良反应.结果 治疗前,两组癌胚抗原(Carcinoembry-onic Antigen,CEA)、神经特异性烯醇化酶(Neuro-specific Enolase,NSE)、胃泌素释放肽前体(Gastrin-releasing Peptide Precursors,ProGRP)水平对比,差异无统计学意义(P均>0.05);治疗后,两组CEA、NSE、ProGRP水平均有下降,观察组分别为(17.36±2.17)ng/mL、(10.06±1.57)µg/L、(9.74±1.81)ng/L,低于对照组的(18.92±2.15)ng/mL、(11.14±1.54)ng/L、(11.15±1.73)µg/L,差异有统计学意义(t=3.989、3.836、4.398,P均<0.001);治疗前,两组肺癌治疗功能评价量表(Functional Assessment Lung Cancer Therapy,FACT-L)和生活质量评估量表(Quality of Life,QOL)评分对比,差异无统计学意义(P均>0.05),治疗后,两组FACT-L、QOL评分均有升高,且观察组高于对照组,差异有统计学意义(t=6.295、7.057,P均<0.001);治疗后,观察组患者不良反应的发生例数较对照组高,但差异无统计学意义(P>0.05).结论 安罗替尼能有效降低晚期NSCLC患者肿瘤标志物水平,控制疾病发展进程,提升患者生存质量,使用后产生的不良反应较小,用药安全性能得到保障.
Effect of Anlotinib Hydrochloride on Quality of Life in Patients with Ad-vanced NSCLC
Objective To explore the effect of anlotinib hydrochloride on quality of life in patients with advanced non-small-cell lung carcinoma(NSCLC).Methods A total of 122 patients with advanced NSCLC treated in Xinyi People's Hospital from January to October 2022 were conveniently selected as the study object.Patients were randomly divided into control group(n=61)and observation group(n=61)by double-blind method.The control group was treated with conventional chemotherapy,and the observation group was treated with conventional chemotherapy combined with anlo-tinib.The level of tumor markers,quality of life and adverse reactions were compared between the two groups.Results Before treatment,the levels of carcinoembryonic antigen(CEA),neurospecific enolase(NSE)and gastrin-releasing peptide precursor(ProGRP)were compared between the two groups,the difference was not statistically significant(all P>0.05).After treatment,the levels of CEA,NSE and ProGRP were decreased in both groups,and the levels in the ob-servation group were(17.36±2.17)ng/mL,(10.06±1.57)µg/L and(9.74±1.81)ng/L,respectively.They were lower than those of the control group(18.92±2.15)ng/mL,(11.14±1.54)ng/L and(11.15±1.73)µg/L,the differences were statisti-cally significant(t=3.989,3.836,4.398,all P<0.001).Before treatment,scores of Functional Assessment of Lung Can-cer Therapy(FACT-L)and Quality of Life(QOL)were compared between the two groups,the differences were not statistically significant(both P>0.05).After treatment,FACT-L and QOL scores were increased in both groups,and the observation group was higher than the control group,the differences were statistically significant(t=6.295,7.057,both P<0.001).After treatment,the number of adverse reactions in the observation group was higher than that in the control group,but there was no significant difference(P>0.05).Conclusion Anlotinib can effectively reduce the level of tumor markers in patients with advanced NSCLC,control the progression of the disease,and improve the quality of life of patients.The adverse reactions caused by the use of anlotinib are small,and the drug safety performance is guaranteed.
Advanced NSCLCAnlotinib hydrochlorideChemotherapyTumor markersQuality of life
万方数据
维普
